Vanda Launches Thetis Study for Nereus™ to Combat GLP-1 Side Effects After Successful Phase 2
Summary
Vanda Pharmaceuticals has initiated the Thetis Study, a new clinical trial for its drug candidate Nereus™, aimed at preventing vomiting induced by GLP-1 receptor agonists. This development is particularly significant as the company also disclosed that a prior Phase 2 study for Nereus™ successfully met its primary endpoint. This positive product development news provides a much-needed boost, following the company's reported increased net loss for 2025 and regulatory setbacks highlighted in its recent 10-K filing and universal shelf registration. For a small-cap biotech, targeting a major side effect of the widely popular GLP-1 drug class represents a substantial potential market opportunity and could significantly de-risk the program. Topline results from the Thetis Study are anticipated by Q4 2026, which will be a key catalyst for the stock.
At the time of this announcement, VNDA was trading at $7.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $430.9M. The 52-week trading range was $3.81 to $9.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.